&#xa0;
defaultWritten evidence submitted by defaultProMeticdefault defaultBioSciencesdefault Ltd default(BTO0012)defaultDeclaration of interest
defaultProMetic
default 
defaultBioSciences
default Ltd has developed products and technology for the capture of 
defaultprion
default infectivity from human blood and plasma products and as a consequence has a financial interest in 
defaultprion
default safety of blood products.
defaultExecutive Summary
default-
default&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; 
defaultProMetic
default Biosciences, in collaboration with the American Red Cross, has developed a technology based upon selective adsorption of 
defaultprion
default proteins which enables the capture of 
defaultvCJD
default infectivity from human blood and blood-derived components and products.
default-
default&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; 
defaultProMetic’s
default  technology, commonly referred to as 
defaultprion
default filtration, has been incorporated into a medical device (P-Capt™) developed in conjunction with and commercialized by 
defaultMacopharma
default SA which provides increased blood safety by removal of 
defaultvCJD
default infectivity (if present) from Red Blood Cell Concentrates (RBC). 
default-
default&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; 
defaultThe P-Capt device obtained CE Mark approval in 2006, and since this time has been under evaluation by the UK’s National Blood Service (NHSBT) but never implemented.
default-
default&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; 
defaultThe same technology, in a different format, has been used successfully by Swiss company 
defaultOctapharma
default AG to provide an increased level of 
defaultprion
default safety for virally-inactivated (S/D-treated) plasma for transfusion.  
defaultOctaplas
default LG™ manufactured using 
defaultProMetic’s
default 
defaultprion
default reduction technology has been approved for human administration in several countries including the UK. 
default-
default&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; 
defaultIn the absence of a commercial blood test with sufficient sensitivity and robustness for use in routine blood donor screening, the adoption of 
defaultprion
default filtration would provide increased protection against the transmission of 
defaultvCJD
default via blood and blood-derived products.
default-
default&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; 
defaultPrion
default reduction technology constitutes a safe and proven approach to improving the safety of blood products independent of the availability of a 
defaultvCJD
default blood screening test.
default&#xa0;defaultJanuary 2014
default&#xa0;default&#xa0;
default&#xa0;
default&#xa0;
default&#xa0;
default Reduction of TSE infectivity from human red blood cells using 
defaultprion
default protein affinity 
defaultligands
default. L 
defaultGregori
default, BC Lambert, PV 
defaultGurgel
default, L 
defaultGheorghiu
default, P 
defaultEdwardson
default, JT Lathrop, C 
defaultMacAuley
default, RG 
defaultCarbonell
default, SJ Burton, D Hammond, RG 
defaultRohwer
default. Transfusion, 46: 1152-1161, 2006.
default Reduction in infectivity of endogenous transmissible spongiform 
defaultencephalopaties
default present in blood by adsorption to selective affinity 
defaultligands
default. L 
defaultGregori
default, PV 
defaultGurgel
default, JT Lathrop, P 
defaultEdwardson
default, BC Lambert, RG 
defaultCarbonell
default, SJ Burton, D Hammond, RG 
defaultRohwer
default.  Lancet, 368: 2226-2230, 2006.
default 
defaultPrion
default removal effect of a specific affinity 
defaultligand
default introduced into the manufacturing process of the pharmaceutical quality solvent/detergent (S/D)-treated plasma 
defaultOctaplasLG
default. A 
defaultNeisser-Svae
default, A Bailey, L 
defaultGregori
default, A 
defaultHeger
default, S Jordan, M 
defaultBehizad
default, H 
defaultReichl
default, J 
defaultRömisch
default, T-E 
defaultSvae
default. 
defaultVox
default 
defaultSanguinis
default, 97: 226-233, 2009.
default Removal of 
defaultprion
default infectivity by affinity 
defaultligand
default chromatography during 
defaultOctaplasLG
default manufacturing – results from animal bioassay studies. A 
defaultHeger
default, A Bailey, A 
defaultNeisser-Svae
default, M 
defaultErtl
default, J 
defaultRömisch
default, T-E 
defaultSvae
default. 
defaultVox
default 
defaultSanguinis
default, 102: 294-301, 2012.
default Infusion of P-Capt 
defaultprion
default-filtered red blood cell products demonstrate acceptable in vivo viability and no evidence of 
defaultneoantigen
default formation. JA 
defaultCancelas
default, N 
defaultRugg
default, PG Pratt, DN 
defaultWorsham
default, JC 
defaultPehta
default, K Banks, RD Davenport, WJ Judd. Transfusion, 51: 2228-2236, 2011.
default In vitro assessment of red-cell concentrates in SAG-M filtered through the 
defaultMacoPharma
default P-CAPT 
defaultprion
default-reduction filter. CV Murphy, E Eakins, J Fagan, H 
defaultCroxon
default, WG Murphy. Transfusion Medicine, 19: 109-116, 2009.
default Phase I/II safety study of transfusion of 
defaultprion
default-filtered red cell concentrates in transfusion-dependent patients. MR Cahill, T Murphy, M Kahn, J Fagan, WG Murphy. 
defaultVox
default 
defaultSanguinis
default, 99: 174-176, 2010.
default Characteristics of 
defaultprion
default-filtered red cells suspended in pathogen-inactivated plasma (MB treated or solvent/detergent treated) for neonatal exchange transfusion. VS 
defaultHornsey
default, C Casey, K McColl, H Young, O Drummond, L McMillan, A Morrison, CV Prowse. 
defaultVox
default 
defaultSanguinis
default, 101: 28-34, 2011.
default 
defaultPrion
default reduction of red blood cells: impact on component quality. M Wiltshire, S Thomas, J Scott, V Hicks, M Haines, P Cookson, M Garwood, R Cardigan.  Transfusion, 50: 970-979, 2010.
default 
defaulthttps://www.gov.uk/government/uploads/system/uploads/attachment_data/file/212250/SaBTO_10_Dec_2012_final.zip
default Safety of a universal, virus-inactivated and 
defaultprion
default-depleted pharmaceutical-quality plasma: a randomized, double-blind, clinical trial in healthy volunteers. P 
defaultJilma-Stohlawetz
default, FW 
defaultKursten
default, C 
defaultWalasek
default, M Horvath, G 
defaultLeitner
default, J List, P 
defaultQuehenberger
default, M 
defaultSchwameis
default, J 
defaultBartko
default, B 
defaultJilma
default. Transfusion, 51: 1228-1240, 2011.
default The effect of 
defaultprion
default reduction in solvent/detergent-treated plasma on haemostatic variables. AS 
defaultLawrie
default, L Green, MT 
defaultCanciani
default, IJ Mackie, F 
defaultPeyvandi
default, MA Scully, SJ 
defaultMachin
default. 
defaultVox
default 
defaultSanguinis
default, 99: 232-238, 2010.
default